$233,588,020

Department of Health and Human Services·National Institutes of Health

ACTION DATE2026-03-26·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75N91020F00039_7529_75N91019D00024_7529

Award description

NIAID COVID-19 ACTIV3

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Funds NIAID COVID-19 therapeutic research and clinical trials through Leidos Biomedical Research.

Sub-sectors

infectious-diseasevaccine-developmentclinical-trials

Why this matters

Sustains U.S. pandemic preparedness and therapeutic development capabilities for emerging infectious diseases.

Supply-chain signal

Indicates continued demand for clinical research infrastructure, laboratory services, and biomedical contract research organizations.

U.S.–China competition angle

Reflects U.S. investment in domestic biomedical research capacity to reduce dependence on foreign pharmaceutical development.

Generated by award_classification v1.0.0 via claude-haiku-4-5-20251001 on 2026-05-14. Cost: $0.001299.

Period of performance

Start

2020-09-02

End

2029-09-29

Status

activein 1233 days

Sources

Award record ingested from usaspending. Source identifier CONT_AWD_75N91020F00039_7529_75N91019D00024_7529.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.